SurModics Inc. and Edge Therapeutics Collaborate on Development of Sustained-Release Neurological Product

EDEN PRAIRIE, Minn. & NEWARK, N.J.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.